Objective In recent years, an increase has been observed in the incidence of bone metastases from hepatocellular carcinoma (HCC). In 2007, our institution established a team approach, which includes the provision of palliative care. In the present study we evaluate the effects of palliative care on the prognosis of HCC patients with bone metastases. Methods The subjects included 44 patients with bone metastases who were treated with radiotherapy be- 
Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer death and has a high incidence in Asian countries, including Japan (1, 2) . The incidence of bone metastases in patients with HCC is reportedly from 6-20% (3, 4); however, this has increased in recent years, possibly owing to advances in primary tumor treatments such as tumor resection, transplantation, transcatheter arterial chemoembolization (TACE), and percutaneous radiofrequency ablation (RFA) (5) , which have improved the long-term survival of patients in whom primary lesions were effectively controlled (6) . In addition, sorafenib (a multikinase inhibitor), has recently been used to treat patients with distant metastases, and has significantly improved the prognosis of patients with advanced HCC (7, 8) . Furthermore, some HCC patients with bone metastases have been reported to survive longer than patients without bone metastases (6) , indicating the importance of controlling the symptoms that are associated with bone metastases and preventing skeletal events in the clinical management of HCC patients with bone metastases. Analgesics and radiotherapy are the major treatments for the pain caused by metastatic bone tumors, and whole-body management is generally best achieved by a team approach that includes palliative care. Although clinicians rarely consider that the benefits of palliative care extend beyond pain relief, these benefits have recently attracted attention. Multiple benefits of palliative care were reported after the 2006 introduction of the Cancer Control Act, which was introduced to improve the quality of life of cancer patients in Japan (9) . However, only a few studies have investigated the effects of palliative care on the prognosis of HCC patients with bone metastases. In 2007, our institution introduced a team approach, which includes palliative care. We herein report our retrospective investigation into the effects of pallia- tive care on the prognosis of HCC patients with bone metastases. Several previous studies have reported important prognostic factors in cancer patients with bone metastases, including successful primary tumor control, a good performance status (PS) at the time of radiotherapy, fewer metastatic bone lesions, and the absence of metastases in other organs (6, (10) (11) (12) (13) . In the present study we therefore examined the effects of various other prognostic factors and the clinical characteristics of bone metastases.
Materials and Methods

Patients and diagnosis
The study population included 44 HCC patients (40 men and 4 women) who received radiotherapy for bone metastases between 2000 and 2014. The age of the subjects ranged from 43-81 years (median: 71 years). The diagnosis of HCC was radiologically confirmed by the presence of hyperattenuation in the arterial phase and washout in the late phase using either contrast enhanced computed tomography (CT) or magnetic resonance imaging (MRI). In cases in which CT and/or MRI diagnoses were inconclusive, ultrasonography and/or hepatic angiography was performed. In addition, whole-body CT was performed to eliminate the possibility of metastatic HCC, and elevated alpha-fetoprotein (AFP) levels and the absence of raised carbohydrate antigen 19-9 levels were considered to confirm a diagnosis of HCC. The diagnosis of metastatic bone tumors was established according to CT and MRI findings and a history of HCC and associated symptoms. Biopsies were not performed for the definitive diagnosis.
Evaluation of pain
Pain was assessed using a numerical rating scale (NRS) according to the response categories proposed by Chow et al. (14) . The patients were asked to rate the intensity of their pain from 0 (no pain) to 10 (the worst pain imaginable). A complete response (CR) was defined as an NRS pain score of 0 at the treated site with no concomitant increase in analgesic intake. A partial response (PR) was defined as a ! 2-point reduction in the pain score at the treated site without an increase in analgesic intake, or with a ! 25% reduction in analgesic intake without increased pain. Pain progression was defined as a ! 2-point increase in the pain score at the treated site without a reduction in analgesic intake, or as a ! 25% increase in analgesic intake without a concomitant decrease in pain. An indeterminate response was defined as a response which did not reflect the definitions of CR, PR, or pain progression (Table 1) .
Palliative radiotherapy
The indications for radiotherapy included intractable pain and/or a high risk of pathological fracture or neurological complications due to cord compression. Multiple-field radiation therapy was performed using 6-or 10-megavolt (MV) photons, depending on the site and depth of the lesion (as determined using CT or MRI). Doses were given in fractions of 2 or 3 Gy/fr with a total dose of 30-50 Gy (median: 39 Gy) depending on the size and site of the lesion. Because various fraction sizes were used, the total doses were recalculated and normalized to biologically effective dose (BED) values. The BED values ranged from 39-60 Gy (median: 48 Gy). The radiation volumes included the gross tumor volumes with 1-1.5 cm margins. For patients with spinal metastases, the radiation portals included the uninvolved vertebral bodies above and below diseased vertebra. Prior to treatment with conventional radiotherapy, a treatment plan was developed for each of the patients based on CT simulations.
Anticancer drugs and analgesics
Although the concomitant administration of anticancer drugs was avoided in most cases, sorafenib was administered to 2 patients before radiotherapy and to 3 patients after radiotherapy. Non-opioid analgesics were administered initially, while mild-moderate or strong narcotic analgesics were subsequently administered as necessary.
Statistical analysis
The statistical significance of the characteristics of the patients who underwent treatment between 2000 and 2006 and after 2007, was calculated using the Wilcoxon rank sum test [for age (years)], and Fisher's exact test (for the remaining categories). The effects of radiotherapy on pain relief and patient survival were analyzed by comparing the patients who received doses above and below the median BED (48 Gy). The survival times after radiotherapy were then calculated, and the number of bone metastases, the sizes of the metastatic lesions (>5 cm or <5 cm), the doses of radiation, the presence of metastasis at other sites, the symptomatic response, PS, the status of the primary tumor, Child-Pugh were compared using the cutoff values of 48 Gy and 5 cm, respectively. The primary status was classified as favorable or unfavorable based on the CT and MRI findings at the start of radiotherapy. The tumor was judged as favorable if it showed no viability. The judgment was made based on the imaging findings without reference to the liver function tests. Tumor markers were also not taken into consideration for the judgment because the elevation of the markers could be attributable to the presence of metastatic lesions. To examine the effects of palliative care on patient prognosis, patients who received conventional care from 2000 to 2006 were compared with those who were treated with the team approach, which included palliative care, from 2007 to 2014. Survival was calculated using the Kaplan-Meier method and differences were confirmed using the log rank test. Independent variables that were found to be statistically significant in a univariate analyses were confirmed using multivariate Cox regression models. Differences in pain responses relative to the dose of radiation were identified using Fisher's exact test. p values of <0.05 were considered to be statistically significant. All calculations and survival analyses were conducted the using SPSS 15.0J statistical software program (SSPS Inc., Chicago, USA).
Results
Demographic characteristics
All 44 patients had bone metastases and suffered some pain. The baseline characteristics of the patients are summarized in Table 2a . The patients who were treated between 2000 and 2006 and after 2007 are summarized in Table 2b . There were significant differences in the characteristics of the patients in the two treatment eras, with the exception of their primary status. No patients underwent surgery or TACE for metastatic bone tumors after radiotherapy or repeated radiotherapy at the same site. Other metastases were detected in the lungs (n=5) and lymph nodes (n=1). The clinical features of the bone metastases from HCC are summarized in Table 3 . The most frequent site of bone metastasis was the spine (n=24; 55%), followed by the pelvic bone (n=9; 20%). The radiographic characteristics of metastatic bone tumors indicated osteolytic lesions in 35 patients (80%) and mixed osteolytic and osteoblastic lesions in 9 patients (20%). Bone metastases with expansile soft-tissue masses were found in 20 patients (45%). Symptoms of acute toxicity due to radiotherapy were rare and mild. Although some patients experienced mild dermatitis or nausea when the digestive tract was included in the irradiated field, there no clear relationships were observed between the symptoms of adverse events and the treatment regimens and/or the total doses; no treatments were specifically associated with the symptoms of acute toxicity.
Responses
The clinical responses of all of the patients are summarized in Table 4 . CR and PR were observed in 8 (18%) and 25 (57%) patients, respectively. Among the 26 patients who received a BED of " 48 Gy or more, 23 (88%) achieved CR or PR. However, among 18 patients who received a BED of <48 Gy, only 10 (56%) showed CR or PR (p=0.031; Table 5).
Predictors of prognosis
The most common causes of death were the progression of HCC and the deterioration of general conditions, and/or hepatic failure due to decreased liver function. No patient died primarily from metastatic bone tumors. The survival time after radiotherapy ranged from 1 to 42 months (median: 4 months; Fig. 1 ). The univariate analyses revealed that the number of bone metastases, the size of the lesions, the dose of radiation, the presence or absence of metastatic lesions other than the bone metastases, and the symptomatic responses were not significant prognostic factors (Table 6 ). Conversely, PS was found to be a significant prognostic factor, and the median survival time (7 months) of patients with a good PS (! 1) was significantly longer than that in patients with poor PS (p=0.005; Fig. 2 ). The median survival time in patients with controlled primary tumors was 8 The p value for patient characteristics was calculated using the Wilcoxon rank sum test for age (years), whereas Fisher's exact test was used for the remaining categories. months, which was significantly longer than in patients with uncontrolled primary tumors (p=0.020; Fig. 3 ). The ChildPugh classification was also a significant prognostic indicator; the median survival in patients with Child-Pugh A was 7 months (p=0.024; Fig. 4) . Finally, the median survival time 
Discussion
In the present study, we investigated the effects of palliative care on the prognosis of HCC patients with bone metastases and clinical characteristics that were associated with pain relief after palliative radiotherapy. The most frequent site of bone metastasis was the spine in 24 patients (55%), and osteolytic lesions were observed in 35 patients (80%). Pain relief and the dose of radiation were found to be significantly associated in patients who received a BED of ! 48 Gy; survival time after radiotherapy ranged from 1-42 months (median: 4 months). Finally, the multivariate analyses identified PS and treatment period as independent prognostic variables.
In agreement with previous reports, the most frequent site of HCC bone metastases was the axial skeleton, including the spine and costal bone (12) . The radiographic characteristics of the metastatic bone tumors of HCC frequently included osteolytic or mixed osteolytic and osteoblastic lesions with hypervascular soft tissue mass formations; pure osteoblastic lesions were rare (12) . Metastatic bone tumors can cause intolerable pain, pathological fractures, and neurological complications due to cord compression. Hence, the increasing incidence of metastatic bone tumors from HCC indicates that greater attention should be paid to the provision of effective treatment.
In 1986, the World Health Organization advocated a three-step ladder for analgesic intake, involving the use of non-opioid analgesics, mild-to-moderate narcotic analgesics, and strong narcotic analgesics. This guideline has become widely used in Japan, where sustained-release morphine tablets were introduced in 1989, followed by fentanyl patches in 2002 and sustained-release oxycodone tablets in 2003. Although these drugs are now commonly used in Japan, the dosages are substantially lower than those used in western countries (15) , potentially reflecting the more frequent use of radiotherapy in the treatment of metastatic bone tumors.
A number of studies have reported the pain relief rates associated with radiotherapy. In particular, Jian et al. (12) reported that the responses of 29.5% and 69.7% of patients were classified as CR and PR, respectively. Similarly, in agreement with previous reports (6, 12, 16) , CR and PR were achieved in 8 (18%) and 25 of the patients (57%) in the present study, respectively; while pain progression was noted in 2 patients (5%) and the responses were indeterminate in 9 patients (20%). In addition, the pain relief rates and the dose of radiation were significantly correlated in patients who received a BED of " 48 Gy. BEDs of 48 Gy are equivalent to 40 Gy in 2-Gy daily fractions, 37.5 Gy in 2.5-Gy daily fractions, or approximately 39 Gy in 3-Gy daily fractions. These doses are compatible with the radiation schedules that are commonly used for metastatic bone tumors in our clinical practice. Although some previous studies have reported that the treatment schedules and total doses of radiotherapy are not associated with treatment effects (17) (18) (19) (20) , the present study suggests that a BED of " 48 Gy may be beneficial, particularly in patients in whom a good prognosis is expected.
The present median survival time after radiotherapy was 4 months, and was shorter than that reported in previous studies (6, 9, 12, 13) . This may reflect the preponderance of advanced metastatic bone tumors and poor general conditions at the start of radiotherapy. Moreover, some patients died early in the study due to the insufficient management of their general conditions after the start of radiotherapy, potentially reducing the median survival time. PS is reportedly an independent prognostic factor for various cancers, including HCC. Accordingly, the survival of patients with a PS score of ! 1 was significantly longer than that of patients with a poor PS score, indicating that general conditions can affect the prognosis. Univariate analyses showed longer survival times in patients with controlled primary lesions than in patients with uncontrolled primary lesions. In addition, survival of patients with Child-Pugh A was significantly longer than that in patients with Child B or C. In previous studies, the leading causes of death in HCC patients with metastatic bone tumors included the progression of hepatic lesions and/ or hepatic failure, although the metastatic tumors were rarely the primary cause of death (13, 21) . Accordingly, death was caused by the progression of the primary disease in most of the present subjects, and deaths were not directly related to the metastatic bone tumors, although two patients died of respiratory failure due to lung metastases and the associated pleural fluid. Therefore, the present data suggest that the main positive prognostic factors were the control of primary tumors, Child-Pugh A and a good PS, indicating that good general conditions were achieved by the efficient control of the primary tumor. Previous studies also show that the AFP levels and times between the primary tumor diagnosis and the development of metastatic bone tumors significantly affect patient survival (12, 13) . These measurements are considered to be indirect indicators of the malignancy and aggressiveness of primary tumors. Few studies have reported the effects of palliative care on the prognosis of HCC patients with bone metastasis. We therefore retrospectively evaluated the effects of the palliative care that was implemented and developed since 2007 in our institution. Survival times among the patients who received care between 2007 and 2014 were significantly longer than among the patients who received care between 2000 and 2006, reflecting improvements of care. Specifically, the median survival time of patients receiving care between 2007 and 2014 was 6 months, which was compatible with survival times in previous studies (6, 9, 12, 13) . The present team approach, which includes palliative care, was initiated in 2003, and the number of patients receiving this care has gradually increased. In 2006, the Ministry of Health, Labour and Welfare developed the basic guidelines to promote anticancer measures based on the Cancer Control Act (article 98), and to disseminate the basic knowledge of palliative care among physicians who are involved in cancer treatment. Subsequently, palliative care workshops have been performed regularly, and the numbers of participants, including the physicians, nurses, and allied professionals, have gradually increased. In these workshops, concerns regarding the need for palliative care have been raised, and after the inception of the Palliative Care Department in our hospital in 2007, there has been a substantial improvement in the quality of palliative care. Until 2006, the physicians in charge played a major role in treatment. In general, they would refer patients to a palliative care team only when certain symptoms occurred. It may be that until that time, most of the physicians treating cancer patients had focused primarily on treatment outcomes and that they had not been fully listening to patients' complaints. After the inception of the Palliative Care Department in our hospital in 2007, there was an increased awareness about the significance of palliative care, which led to an increase in early intervention by the palliative care team. Currently, the Palliative Care Department is composed of physicians, nurses, pharmacists, and allied professionals, including clinical psychologists. The palliative care team has been involved, not only in pain control, but also in the treatment of paralysis, psychiatric care, advice for pain control and whole-body management, treatment of lymphedema, aromatherapy for healing, and advice regarding medication and lifestyle changes after discharge. At present, the palliative care team plays an important role in multidisciplinary team care in collaboration with the physicians in charge. In 2008, the Japanese Society for Palliative Medicine set up the Palliative Care Emphasis program as part of the Symptom Management and Assessment for Continuous medical Education project, which was based on the policies of the Cancer Control Act of the Japanese Government (22) . This program has led to improvements in the skills of concerned professionals, including surgeons, and ensuing educational opportunities have enhanced pallia-tive care in our institution. Previously, palliative care was primarily provided for patients with advanced cancer, but since 2007 the provision of intensive care in collaboration with the physician in-charge and allied professionals has been extended to the care of patients with early-stage cancer. Taken together, we believe that the development of a team approach to palliative care changed the attitudes of physicians regarding palliative care. Until then, the physicians in charge had been focusing only on palliation. They are currently aware of the importance of whole-body management, including pain control. We also believe that the advice provided by the palliative care team regarding medication and whole-body management led to an improvement in the general conditions of HCC patients with bone metastases, resulting in their increased survival. The present study was associated with some limitations, including its relatively small sample size. However, we believe that palliative care should be implemented as part of the treatment regime for HCC patients in all institutions. However, further large-scale studies are required to confirm the positive prognostic effects of palliative care.
Conclusion
The present study showed the significantly improved survival time in HCC patients with metastatic bone tumors who received palliative care between 2007 and 2014, in comparison to those treated with conventional care between 2000 and 2006. We therefore suggest that palliative care, including radiotherapy for pain relief, improves the prognosis of HCC patients with metastatic bone tumors by improving their general conditions.
